Status:
COMPLETED
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
Lead Sponsor:
ShangHai Ji Ai Genetics & IVF Institute
Conditions:
IVF
GnRH Antagonist
Eligibility:
FEMALE
20-43 years
Phase:
PHASE3
Brief Summary
Progestin can inhibit the pituitary LH surge during ovarian stimulation and various studies show progestin-primed ovarian stimulation (PPOS) is effective in blocking the LH surge in IVF. More and more...
Eligibility Criteria
Inclusion
- Age of women \<43 years at the time of ovarian stimulation for IVF
- The first IVF cycle
- Antral follicle count (AFC) \>15 on day 2-5 of the period
Exclusion
- Presence of a functional ovarian cyst with E2\>100 pg/mL
- Recipient of oocyte donation
- Undergoing preimplantation genetic testing
- Presence of hydrosalpinx or endometrial polyp which is not surgically treated
Key Trial Info
Start Date :
June 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2022
Estimated Enrollment :
784 Patients enrolled
Trial Details
Trial ID
NCT04414761
Start Date
June 4 2020
End Date
October 10 2022
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ShangHai JIAI Genetics&IVF Institute
Shanghai, China